Brassica rapa L. Polysaccharides Alleviate T2D via Modulation of Gut Microbiota and Metabolites
Wei Li1, Xinyao Han1, Wei Wang1
1College of Food Science and Pharmacy, Xinjiang Agricultural University, Urumqi 830052, China.
Abstract:
The present research sought to investigate the impacts of Brassica rapa L. polysaccharide (Brp) on glycolipid metabolism in diabetic rats and the regulatory role of gut microbiota in metabolic balance. After 30-day Brp gavage, glycolipid metabolic parameters and amino acid levels were measured, and gut microbial communities were sequenced and analyzed. The results showed that Brp improved glycolipid metabolism, alleviated insulin resistance and hepatic oxidative stress, increased liver glycogen synthesis, and modulated gut microbiota composition. Specifically, Brp potentially enhanced short-chain fatty acid (SCFAs) production by enriching Blautia and Roseburia populations while reducing lipopolysaccharide (LPS)-producing bacteria to lower pathological risks. Notably, Brp may reduce the risk of T2D by increasing the concentration of lysophosphatidic acid (18:2(9Z,12Z)/0:0), indoleacrylic acid, cholic acid, and betaine, and decreasing high-risk metabolites such as 3,4-dihydroxybutyrate, xanthine, and carnitine, as well as regulating branched-chain amino acids and aromatic amino acids throughout the development of T2D.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational
Dipeptidyl Peptidase 4 Inhibitors


